AstraZeneca entered into an agreement with Swiss-based Covis Pharma B.V. to sell its rights to the medicines Alvesco, used for the treatment of persistent asthma, and Omnaris and Zetonna used for the treatment of nasal symptoms associated with rhinitis (hay fever).
The rights cover markets outside the US and the US royalties for the medicines.
Covis Pharma currently commercializes Alvesco, Omnaris and Zetonna in the US and will become the owner of the medicines upon closing. The transaction does not include the transfer of any AstraZeneca employees or facilities.
Mark Mallon, AZ’s executive vice president, Global Product and Portfolio Strategy, said: “One of our strategic objectives is to divest parts of our portfolio, allowing us to allocate resources to develop innovative new medicines to address unmet patient needs. Covis Pharma has strong capabilities in marketing medicines around the world, and our agreement with them means patients will continue to benefit from Alvesco, Omnaris and Zetonna.”
Michael Porter, CEO, Covis Pharma, said: “This is an exciting milestone for Covis Pharma and aligned with our strategy to build a global respiratory/allergy franchise. When we acquired the US rights for Alvesco, Omnaris and Zetonna in 2017, we recognized the importance of these medicines in the respiratory and allergy therapeutic area and we look forward to extending our reach to meet the needs of patients and physicians around the world.”
Alvesco is an inhaled anti-inflammatory maintenance therapy delivered by a metered-dose inhaler to help control persistent asthma.
Omnaris and Zetonna are nasal sprays for the treatment of nasal symptoms associated with seasonal allergic and allergic/non-allergic perennial rhinitis.
Covis Pharma will pay AstraZeneca $350 million upon closing, in addition to conditional sales-related payments of up to $21 million over four years from 2019. The agreement is subject to customary closing conditions and is expected to complete by the end of 2018.
As AstraZeneca will not maintain a significant ongoing interest in the medicines following completion, the payments will be recognized as Other operating income in the company’s financial statements. Combined 2017 Product Sales of Alvesco,Omnaris and Zetonna, recorded by AstraZeneca, were $106 million. The agreement does not affect the company’s financial guidance for 2018.
AstraZeneca employs 1,500 in Delaware.
